Crossmark

Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance

Crossref DOI link: https://doi.org/10.1007/s12325-026-03502-w

Published Online: 2026-02-20

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ito, Tomohiro https://orcid.org/0000-0002-6456-2825
Shibuya, Akira

Noguchi, Hiroko
Funding

Funding for this research was provided by:

Nippon Boehringer Ingelheim Co. Ltd
License Information

Text and Data Mining valid from 2026-02-20

Version of Record valid from 2026-02-20
More Information

Article History

Received: 17 November 2025

Accepted: 14 January 2026

First Online: 20 February 2026

Declarations

:

: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) as supported by Good Publication Practice (GPP) guidelines. Tomohiro Ito and Hiroko Noguchi are employees of Nippon Boehringer Ingelheim Co., Ltd. Akira Shibuya is an employee of EPS Co., Ltd.

: The study was conducted in accordance with the Ministry of Health, Labour and Welfare Good Post-Marketing Study Practice, and Good Vigilance Practice ordinances. Under these regulations, neither informed consent from patients nor ethics approval were required, as this was a non-interventional observational study using anonymized data.

Document is current

Any future updates will be listed below